Headlines:
Tag: Phase
Pharming Announces Initiation of Clinical Phase I/II Pre-Eclampsia Study

Pharming Announces Initiation of Clinical Phase I/II Pre-Eclampsia Study

June 11, 2019 Economie

LEIDEN, Netherlands, June 11, 2019 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") today announces that, following receipt of the Dutch investigating ...

Lees verder
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton´s Tyrosine Kinase (BTK) Inhibitor to Repor

Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton´s Tyrosine Kinase (BTK) Inhibitor to Repor

May 11, 2019 Economie

Not intended for U.S. media -- 48-week results provide additional evidence of relapse reduction for investigational evobrutinib -- Evobrutinib demonstrated ...

Lees verder
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of

February 17, 2019 Economie

Not intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 16, 2019 /PRNewswire/ -- -- JAVELIN Renal 101 shows significant improvement in ...

Lees verder
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

August 4, 2018 Economie

LONDON, August 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet ...

Lees verder
Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

July 26, 2018 Economie

TAIPEI, Taiwan, July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ...

Lees verder
ENDOSCOPY Publishes the MORA Phase III Trial for PLENVU® (NER1006), the Only 1 Litre Peg Based Bowel Preparation[i]

ENDOSCOPY Publishes the MORA Phase III Trial for PLENVU® (NER1006), the Only 1 Litre Peg Based Bowel Preparation[i]

July 21, 2018 Economie

AMSTERDAM, July 19, 2018 /PRNewswire/ -- Norgine B.V. today announced that results from the PLENVU(R) Phase III MORA trial were published in ENDOSCOPY, a monthly peer-reviewed ...

Lees verder
McLaren Launches the Next Phase of its Pioneering esports Programme

McLaren Launches the Next Phase of its Pioneering esports Programme

July 9, 2018 Economie

LONDON, July 9, 2018 /PRNewswire/ -- The most open and inclusive racing esports tournament on the planet - global participation, multiple platforms, the biggest games. Twelve ...

Lees verder
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

June 30, 2018 Economie

TOKYO, June 29, 2018 /PRNewswire/ -- Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 ...

Lees verder
Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

June 5, 2018 Economie

AMSTERDAM, June 5, 2018 /PRNewswire/ -- Norgine B.V. today with its partner Salix Pharmaceuticals, Ltd. ("Salix"), announced that they will present new data from phase 3 ...

Lees verder
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

May 18, 2018 Economie

NOVATO, California, TOKYO and LONDON, May 17, 2018 /PRNewswire/ -- Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients ...

Lees verder
Nieuwe berichten
BizPress.nl